Agile Therapeutics Return on Investment 2013-2023 | AGRX
Current and historical return on investment (ROI) values for Agile Therapeutics (AGRX) over the last 10 years.
| Agile Therapeutics ROI - Return on Investment Historical Data |
| Date |
TTM Net Income |
LT Investments & Debt |
Return on Investment |
| 2023-12-31 |
$-0.02B |
|
inf% |
| 2023-09-30 |
$-0.02B |
|
inf% |
| 2023-06-30 |
$-0.04B |
|
inf% |
| 2023-03-31 |
$-0.04B |
|
inf% |
| 2022-12-31 |
$-0.05B |
|
inf% |
| 2022-09-30 |
$-0.07B |
|
inf% |
| 2022-06-30 |
$-0.07B |
|
-962.96% |
| 2022-03-31 |
$-0.07B |
|
-417.65% |
| 2021-12-31 |
$-0.07B |
|
-238.66% |
| 2021-09-30 |
$-0.07B |
$0.03B |
-142.70% |
| 2021-06-30 |
$-0.07B |
$0.04B |
-108.33% |
| 2021-03-31 |
$-0.06B |
$0.05B |
-78.38% |
| 2020-12-31 |
$-0.05B |
$0.07B |
-56.98% |
| 2020-09-30 |
$-0.04B |
$0.08B |
-54.74% |
| 2020-06-30 |
$-0.03B |
$0.10B |
-55.17% |
| 2020-03-31 |
$-0.02B |
$0.11B |
-83.02% |
| 2019-12-31 |
$-0.02B |
|
inf% |
| 2019-09-30 |
$-0.02B |
|
inf% |
| 2019-06-30 |
$-0.02B |
|
inf% |
| 2019-03-31 |
$-0.02B |
|
inf% |
| 2018-12-31 |
$-0.02B |
|
inf% |
| 2018-09-30 |
$-0.02B |
|
inf% |
| 2018-06-30 |
$-0.03B |
|
-212.77% |
| 2018-03-31 |
$-0.03B |
|
-128.57% |
| 2017-12-31 |
$-0.03B |
|
-83.72% |
| 2017-09-30 |
$-0.03B |
$0.05B |
-63.74% |
| 2017-06-30 |
$-0.03B |
$0.04B |
-59.79% |
| 2017-03-31 |
$-0.03B |
$0.05B |
-54.30% |
| 2016-12-31 |
$-0.03B |
$0.05B |
-48.39% |
| 2016-09-30 |
$-0.03B |
$0.06B |
-52.10% |
| 2016-06-30 |
$-0.03B |
$0.06B |
-58.15% |
| 2016-03-31 |
$-0.03B |
$0.07B |
-60.27% |
| 2015-12-31 |
$-0.03B |
$0.04B |
-62.56% |
| 2015-09-30 |
$-0.03B |
$0.05B |
-57.94% |
| 2015-06-30 |
$-0.03B |
$0.06B |
-50.91% |
| 2015-03-31 |
$-0.02B |
$0.06B |
-40.89% |
| 2014-12-31 |
$-0.02B |
$0.05B |
-44.72% |
| 2014-06-30 |
$-0.01B |
$0.06B |
-52.46% |
| 2014-03-31 |
$-0.01B |
|
inf% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.003B |
$0.020B |
|
Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. It is focused on the development and commercialization of new prescription contraceptive products. The Company's lead product candidate is Twirla (TM), also known as AG200-15, a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Agile Therapeutics, Inc. is headquartered in Princeton, New Jersey.
|
